非小细胞肺癌；新辅助化疗；个体化治疗；基因表达；液相芯片

Li Zhe; Ren Qingquan; Liu Yanfeng; Xu Ruibin; Wang Xin; Zhang Lanjun

您当前的位置：

首页 >

文章列表页 >

非小细胞肺癌；新辅助化疗；个体化治疗；基因表达；液相芯片

更新时间：2023-12-22

- 非小细胞肺癌；新辅助化疗；个体化治疗；基因表达；液相芯片
- Journal of Chongqing Medical University Vol. 43, Issue 6, Pages: 772(2018)
- 作者机构：
  
  1. 延安大学附属医院胸外科,延安,716000
  2. 中山大学肿瘤防治中心胸科、华南肿瘤学国家重点实验室,广州,510060
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2018，
扫描看全文
Li Zhe, Ren Qingquan, Liu Yanfeng, et al. 非小细胞肺癌；新辅助化疗；个体化治疗；基因表达；液相芯片. [J]. Journal of Chongqing Medical University 43(6):772(2018)
DOI：

Li Zhe, Ren Qingquan, Liu Yanfeng, et al. 非小细胞肺癌；新辅助化疗；个体化治疗；基因表达；液相芯片. [J]. Journal of Chongqing Medical University 43(6):772(2018) DOI：

摘要

目的：本研究拟通过结合目前指导个体化治疗的5个分子生物学指标对接受过新辅助化疗的ⅢA-N2期非小细胞肺癌（non-small-cell lung cancer，NSCLC）患者进行回顾性研究，评估目前NSCLC个体化治疗靶标的价值及临床意义。方法：用分支DNA-液相芯片法（bDNA-LCT）检测30例ⅢA-N2期NSCLC新辅助化疗后手术切除的肿瘤组织标本中ERCC1、BRCA1、TYMS、RRM1、TUBB3基因的mRNA表达情况，对各基因表达情况与患者新辅助化疗疗效间进行分析，探讨多基因表达对新辅助化疗的指导意义。结果：30例肿瘤组织标本中ERCC1、BRCA1、TYMS、RRM1、TUBB3基因mRNA低表达率分别为10.0%、33.3%、46.7%、46.7%、36.7%；中偏低表达率分别为16.7%、20.0%、23.3%、13.3%、16.7%；中表达率分别为40.0%、13.3%、23.3%、30.0%、26.7%；中偏高表达率分别为6.7%、16.7%、0.0%、6.7%、3.3%；高表达率分别为26.7%、16.7%、6.7%、3.3%、16.7%。统计分析显示各基因mRNA表达间存在明显的相关性（P<0.05）。ERCC1及TUBB3的mRNA表达与化疗疗效间有明显的关系（P=0.019，P=0.001）；在24例行抗微管类/铂类新辅助化疗的患者中，RRM1及TUBB3的mRNA表达与化疗疗效间有明显的关系（P=0.039，P=0.000）。结论：NSCLC中多基因mRNA表达间存在明显的相关性；对IIIA-N2期NSCLC患者行新辅助化疗前所获取的肿瘤组织标本进行个体化基因mRNA表达检测，筛选出合理指标所指导的化疗方案，可以提高新辅助化疗疗效。

Abstract

Objective：To discuss the efforts towards personalizing delivery of care based on the mRNA expression levels of ERCC1，BRCA1，TYMS，RRM1 and TUBB3 by choosing neoadjuvant chemotherapy for 30 ⅢA-N2 non-small-cell lung cancer（NSCLC） pa－tients. Methods：Postoperative samples from 30 ⅢA-N2 NSCLC patients treated with neoadjuvant chemotherapy were analyzed. mRNA expressions of ERCC1，BRCA1，TYMS，RRM1 and TUBB3 were detected by using branched DNA-liquidchip technology（bDNA-LCT）. Results：The total expressions of 5 genotypes from low to high were detected. Correlations were observed between most of these gene expression levels（P<0.05）. All patients were treated with platinum-based neoadjuvant chemo-therapy. ERCC1 and TUBB3 mRNA expressions were associated with the efficacy of neoadjuvant chemotherapy（P<0.05）；lower expression can predict better response. Among these 24 patients treated with antimicrotubules/platinum based chemotherapy，the mRNA expression levels of RRM1 and TUBB3 could be used to predict the treatment outcomes of chemotherapy（P<0.05）. Conclusion：A clear correlation exists between many genes mRNA expression in NSCLC. The mRNA expression levels of many genes could be detected as predictors of the response to neoadjuvant chemotherapy.

关键词

非小细胞肺癌新辅助化疗个体化治疗基因表达液相芯片

Keywords

non-small-cell lung cancerneoadjuvant chemotherapyindividual therapygene expressionbranched DNA-liquidchip technology

references

Views

107

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pathomics signature based on machine learning can predict the response to neoadjuvant chemotherapy in breast cancer patients

Effect of connexin 43 on the primary resistance to gefitinib in non-small-cell lung cancer cells

c-myc/N-ras/P₅₃ mRNA expression in erythro-leukemia cell line in relation to its cytobiological features

Cloning and expression of human endostatin

The cDNA clone of the coding region of rat augmenter of liver regeneration gene and its prokaryotic expression

Related Author

Zhang Jieqiu

Wu Qi

Wang Jianmei

Yao Xiaopeng

Luo Yanmei

Luo Min

Teng Cuifang

Huang Guolin

Related Institution

Department of Medical Engineering Technology，School of Medical Information and Engineering，Southwest Medical University

Department of Pathology，The Affiliated Hospital of Southwest Medical University

Department of Epidemiology and Health Statistics， School of Public Health，Southwest Medical University

Department of Pharmacology,School of Pharmacy,Guangxi Medical University

Department of Clinical Biochemistry, College of Basic Medicine

⁰